

Illuminating *the* Journey™

Johnson & Johnson VISION

LipiFlow®
THERMAL PULSATION

Ask your doctor if you have MGD
and if LipiFlow® is right for you.



Johnson & Johnson VISION

Dry Eye *and* MGD

Talk to Your Doctor Today.

LipiFlow® is a trademark of TearScience, Inc.
© Johnson & Johnson Surgical Vision, Inc. 2018
PP2018TS4143 – Canada

An Answer for Millions with Dry Eye


There are over 340 million people worldwide who suffer from dry eye.[1] Many have learned to live with eye discomfort and have become dependent on drops or other treatment methods that offer short-term relief. This has been due to a lack of understanding that a leading cause of dry eye is now understood to be Meibomian Gland Dysfunction or MGD.

Understanding MGD

Many commonly attribute their eye discomfort to dry eye, when a leading cause of the burning, scratching and redness is MGD.


MGD occurs when there is compromise to the function and/or structure of the Meibomian glands. These glands, located in the eyelids produce the protective oily (lipid) layer of the tear film. This oil helps protect the surface of the eye from disease and prevents the watery part of the tears from evaporating when your eyes are open. Without these oils, the eyes become more susceptible to the negative effects that dry climates, air conditioning, computer use, reading and other daily activities can have on the long-term health of our eyes.

MGD is a prevalent, chronic and progressive disease.[2,3,4,5] MGD can be asymptomatic, particularly in its early stages.[6] Routine assessments of meibomian gland function and structure may facilitate early intervention and minimize the negative impact of MGD on patient quality of life.



Treating MGD with LipiFlow®

LipiFlow® is a 12-minute treatment performed in your doctor's office designed to remove blockages from the Meibomian glands, allowing them to properly function and produce the oils that make up the top protective lipid layer of the tear film.



LipiFlow® Activators are single-use sterile devices that safely and comfortably deliver a combination of heat to the inner lids and simultaneous therapeutic motion to the outer lids, removing blockages from the Meibomian glands.[7] The Activators are contoured to avoid contact with the cornea, protecting the delicate structures of the eye.

After initial numbing drops, the LipiFlow® procedure offers a drug-free mechanism of action. Removing blockages allows the glands to resume production of oil or lipids. This oil is essential for a healthy tear film, stable vision, and ocular comfort. Maximum results are usually experienced 6-8 weeks after treatment.

1. Market Scope 2016 Dry Eye Report
2. Korb DR, Henriquez AS. Meibomian gland dysfunction and contact lens intolerance. J Am Optom Assoc. 1980 Mar;51(3):243-51.
3. Schaumberg DA, Nichols JJ, Papas EB et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1994-2005.
4. Nichols KK, Hanlon SD, Nichols JJ. A murine model for characterizing glandular changes in obstructive meibomian gland dysfunction. ARVO. 2014; Abstract #14-A0002.
5. Lemp, M. A., Crews, L. A., Bron, A. J., et al. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort. Cornea. 2012; 31(5): 472-478.
6. Blackie CA, Korb DR, Knop E, Bedi R, Knop N, Holland EJ. Nonobvious obstructive meibomian gland dysfunction (NOMGD). Cornea 2010;29(12):1333-45.
7. Blackie C, Carlson AN, Korb DR. Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation: a review. Current Opinion in Ophthalmology. 2015; 26(4):306-13.

